Institutional members access full text with Ovid®

Share this article on:

Two New Drugs for Chronic Hepatitis C

Aschenbrenner, Diane S. MS, RN

AJN The American Journal of Nursing: September 2011 - Volume 111 - Issue 9 - p 22
doi: 10.1097/01.NAJ.0000405053.00454.26
Drug Watch
  • Two new protease inhibitors that specifically target the hepatitis C virus have recently been approved: telaprevir (Incivek) and boceprevir (Victrelis). Both drugs are added to standard chronic hepatitis C treatment to improve the therapeutic response; they're not used as monotherapy.
  • Food containing 20 g of fat must be eaten 30 minutes before taking telaprevir.
  • Boceprevir can be taken just before, during, or just after a meal, with no dietary restrictions.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch:

© 2011 Lippincott Williams & Wilkins, Inc.